MARKET

CGTX

CGTX

COGNITION THERAPEUTICS INC
NASDAQ
0.3252
+0.0101
+3.21%
After Hours: 0.3199 -0.0053 -1.63% 19:43 05/16 EDT
OPEN
0.3280
PREV CLOSE
0.3151
HIGH
0.3289
LOW
0.3100
VOLUME
386.09K
TURNOVER
--
52 WEEK HIGH
2.950
52 WEEK LOW
0.2800
MARKET CAP
20.16M
P/E (TTM)
-0.4429
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CGTX last week (0505-0509)?
Weekly Report · 6d ago
Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down
NASDAQ · 05/09 15:46
Cognition Therapeutics presents preclinical data on zervimesine at ARVO
TipRanks · 05/09 11:36
Cognition Therapeutics Reports Preclinical Data At ARVO Showing Potential For Zervimesine To Protect RPE Cells From Damage In Dry AMD
Benzinga · 05/09 11:33
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
Barchart · 05/09 06:30
Cognition Therapeutics Reports Q1 2025 Financials and Progress
TipRanks · 05/09 04:53
Cognition Therapeutics GAAP EPS of -$0.14 misses by $0.04
Seeking Alpha · 05/08 15:33
Cognition Therapeutics reports results from Phase 2 COG2201 trial
TipRanks · 05/08 12:50
More
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.

Webull offers Cognition Therapeutics Inc stock information, including NASDAQ: CGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGTX stock methods without spending real money on the virtual paper trading platform.